Praxis Precision Medicines to Present at BofA Securities 2022 Healthcare Conference
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
SUNNYVALE, Calif., May 04, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular…
Product theater presentation will be held on May 7 to highlight clinical data and attributes…
CAMARILLO, Calif., May 04, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech…
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 04, 2022 (GLOBE NEWSWIRE) — Gracell…
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage…
Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan…
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
ZUG, Switzerland and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell…
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
NEWTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage,…
Immediate revenue and expansion of global footprint Acquisition transforms Aspargo into a revenue producing company…
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP),…
LONDON, May 04, 2022 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical…
Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Described new understanding…
AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT…
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical…
– VCN-11 incorporates a proprietary albumin binding domain in the virus shell with the potential…